Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

Trial Profile

Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Bazedoxifene (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VIOLINE
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 14 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.
    • 14 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top